loading
전일 마감가:
$57.73
열려 있는:
$58.01
하루 거래량:
1.17M
Relative Volume:
0.64
시가총액:
$11.46B
수익:
$4.08B
순이익/손실:
$32.48M
주가수익비율:
415.79
EPS:
0.14
순현금흐름:
$16.80M
1주 성능:
+5.51%
1개월 성능:
-6.13%
6개월 성능:
-12.37%
1년 성능:
+10.41%
1일 변동 폭
Value
$57.08
$58.69
1주일 범위
Value
$55.11
$59.95
52주 변동 폭
Value
$50.35
$83.95

인사이트 코퍼레이션 Stock (INCY) Company Profile

Name
명칭
Incyte Corp
Name
전화
(302) 498-6700
Name
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
직원
2,617
Name
트위터
@Incyte
Name
다음 수익 날짜
2025-02-10
Name
최신 SEC 제출 서류
Name
INCY's Discussions on Twitter

INCY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
INCY
Incyte Corp
58.21 11.46B 4.08B 32.48M 16.80M 0.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-18 다운그레이드 Guggenheim Buy → Neutral
2025-03-18 다운그레이드 William Blair Outperform → Mkt Perform
2024-12-17 개시 UBS Neutral
2024-10-29 업그레이드 BofA Securities Neutral → Buy
2024-10-01 개시 Wolfe Research Outperform
2024-09-18 다운그레이드 Truist Buy → Hold
2024-07-02 다운그레이드 BMO Capital Markets Market Perform → Underperform
2024-05-23 개시 Deutsche Bank Hold
2024-04-23 개시 Cantor Fitzgerald Neutral
2024-02-23 개시 Jefferies Buy
2024-02-14 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 업그레이드 Leerink Partners Market Perform → Outperform
2023-12-04 업그레이드 Guggenheim Neutral → Buy
2023-11-21 다운그레이드 Goldman Buy → Neutral
2023-07-25 개시 Citigroup Buy
2023-05-04 다운그레이드 BofA Securities Buy → Neutral
2023-04-10 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2023-03-24 업그레이드 SVB Securities Underperform → Market Perform
2023-01-31 개시 Piper Sandler Overweight
2022-08-03 다운그레이드 Evercore ISI Outperform → In-line
2022-08-03 다운그레이드 Guggenheim Buy → Neutral
2022-07-28 개시 Wells Fargo Equal Weight
2022-02-09 다운그레이드 SVB Leerink Mkt Perform → Underperform
2022-01-18 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2021-11-19 개시 BMO Capital Markets Market Perform
2021-07-20 업그레이드 The Benchmark Company Hold → Buy
2021-02-10 다운그레이드 SVB Leerink Mkt Perform → Underperform
2021-01-07 개시 Truist Buy
2021-01-04 업그레이드 Guggenheim Neutral → Buy
2020-06-16 개시 The Benchmark Company Hold
2020-05-06 다운그레이드 JP Morgan Overweight → Neutral
2020-04-29 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-04-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-03-24 재개 William Blair Outperform
2020-03-13 업그레이드 BofA/Merrill Neutral → Buy
2020-02-04 재개 BofA/Merrill Neutral
2020-01-03 재확인 BMO Capital Markets Market Perform
2020-01-03 다운그레이드 Mizuho Buy → Neutral
2020-01-02 다운그레이드 Guggenheim Buy → Neutral
2019-10-03 개시 Mizuho Buy
2019-09-12 개시 BMO Capital Markets Market Perform
2019-09-05 업그레이드 JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 재개 Morgan Stanley Equal-Weight
2019-09-05 업그레이드 Oppenheimer Perform → Outperform
2019-05-21 개시 Credit Suisse Neutral
2019-05-03 다운그레이드 Barclays Overweight → Equal Weight
2019-04-11 개시 Stifel Hold
2019-04-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2019-01-24 업그레이드 William Blair Mkt Perform → Outperform
모두보기

인사이트 코퍼레이션 주식(INCY)의 최신 뉴스

pulisher
Apr 18, 2025

Incyte Grants Restricted Stock Units to New Employees - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.

Apr 18, 2025
pulisher
Apr 17, 2025

Incyte Can Get Novartis' Privileged Info On Drug Royalty Deal - Law360

Apr 17, 2025
pulisher
Apr 16, 2025

Incyte Earnings Preview: What to Expect - Inkl

Apr 16, 2025
pulisher
Apr 16, 2025

Incyte Earnings Preview: What To Expect - Barchart.com

Apr 16, 2025
pulisher
Apr 15, 2025

Incyte to Announce Q1 2025 Financial Results on April 29 - MSN

Apr 15, 2025
pulisher
Apr 14, 2025

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Apr 14, 2025
pulisher
Apr 13, 2025

Incyte (INCY) Revenue Surges, But Stock Drops 20% - GuruFocus

Apr 13, 2025
pulisher
Apr 11, 2025

Global Janus Kinase Inhibitors Market Surges at 8.4% CAGR - openPR.com

Apr 11, 2025
pulisher
Apr 11, 2025

Incyte to Report First Quarter Financial Results | INCY Stock Ne - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Incyte to Report First Quarter Financial Results - Business Wire

Apr 10, 2025
pulisher
Apr 09, 2025

Judges Skeptical of Incyte's Patent Block on Sun's Alopecia Drug - Bloomberg Law News

Apr 09, 2025
pulisher
Apr 08, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 7, 2025 - BioSpace

Apr 08, 2025
pulisher
Apr 07, 2025

Incyte Can't Get Pretrial Win In Novartis Royalty Fight - Law360

Apr 07, 2025
pulisher
Apr 07, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY) - Yahoo Finance

Apr 07, 2025
pulisher
Apr 03, 2025

Incyte Co. (NASDAQ:INCY) Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat

Apr 03, 2025
pulisher
Apr 02, 2025

Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com

Apr 02, 2025
pulisher
Apr 02, 2025

Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com

Apr 02, 2025
pulisher
Apr 02, 2025

1,764,725 Shares in Incyte Co. (NASDAQ:INCY) Acquired by Norges Bank - MarketBeat

Apr 02, 2025
pulisher
Apr 01, 2025

Incyte Stock: Is INCY Outperforming the Health Care Sector? - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Incyte Stock: Is INCY Outperforming The Health Care Sector? - Barchart.com

Apr 01, 2025
pulisher
Apr 01, 2025

3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Women in healthcare and life sciences - The Business Journals

Mar 31, 2025
pulisher
Mar 31, 2025

Incyte’s SWOT analysis: stock faces patent cliff challenge amid pipeline promise - Investing.com

Mar 31, 2025
pulisher
Mar 30, 2025

Meiji Yasuda Asset Management Co Ltd. Purchases 32,830 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

Incyte : U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir - MarketScreener

Mar 30, 2025
pulisher
Mar 27, 2025

Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment - MSN

Mar 27, 2025
pulisher
Mar 26, 2025

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Mar 26, 2025
pulisher
Mar 24, 2025

Incyte Had a Bad Week. Investors Are Used to It. - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Incyte’s Hold Rating: Balancing Pipeline Challenges and Established Product Valuation - TipRanks

Mar 24, 2025
pulisher
Mar 23, 2025

Compass Ion Advisors LLC Has $960,000 Position in Incyte Co. (NASDAQ:INCY) - MarketBeat

Mar 23, 2025
pulisher
Mar 22, 2025

Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts - TipRanks

Mar 22, 2025
pulisher
Mar 21, 2025

Why Incyte Stock Was Tanking This Week - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Incyte (INCY) Stock Declines Due to Clinical Trial Results - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance

Mar 21, 2025
pulisher
Mar 19, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Stock market unimpressed by results for Incyte acne drug as share price drops 11% - delawarebusinessnow.com

Mar 19, 2025
pulisher
Mar 19, 2025

Incyte price target lowered to $72 from $74 at Truist - Yahoo Finance

Mar 19, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BMV:INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BIT:1INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib (NASDAQ:INCY) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Marginal Zone Lymphoma Pipeline 2025: MOA and ROA Insights, - openPR

Mar 18, 2025
pulisher
Mar 18, 2025

INCY Stock Down on Disappointing Skin Disease Study Data - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte stock price target cut to $72 at Truist Securities - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte’s JAK1 blocker meets goals in Phase III trials - The Pharma Letter

Mar 18, 2025
pulisher
Mar 18, 2025

Jefferies cuts Incyte stock price target to $75, keeps Buy rating - Investing.com

Mar 18, 2025

인사이트 코퍼레이션 (INCY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
자본화:     |  볼륨(24시간):